Last Updated : September 19, 2024
Details
Generic Name:
delgocitinib
Project Status:
Pending
Therapeutic Area:
Chronic hand eczema
Manufacturer:
LEO Pharma Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
SR0875-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of moderate to severe chronic hand eczema (CHE), including the relief of pain and pruritus, in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.
Fee Schedule:
Pending
Indications:
For the treatment of moderate to severe chronic hand eczema (CHE), including the relief of pain and pruritus, in adults who have had an inadequate response to, or for whom topical corticosteroids are not advisable.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : September 19, 2024